Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of March 28, 2025 • 6:30 AM ET

Date/Time Source News Release
03/20/2025 06:00 PM EDT PR Newswire Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
03/12/2025 04:15 PM EDT PR Newswire Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
03/05/2025 06:00 PM EST PR Newswire Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets
02/26/2025 07:00 AM EST PR Newswire Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata
02/24/2025 07:00 AM EST PR Newswire Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
02/24/2025 07:00 AM EST PR Newswire Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
02/10/2025 07:00 AM EST PR Newswire Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
01/10/2025 07:00 AM EST PR Newswire Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
12/07/2024 12:00 PM EST PR Newswire Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
11/18/2024 03:30 PM EST PR Newswire Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence
Page

Additional News

As of March 28, 2025 • 6:30 AM ET

Date/Time Source News Release
03/14/2025 09:28 AM EDT SeekingAlpha Nektar upgraded at Oppenheimer on upcoming mid-stage trial readout
03/14/2025 07:33 AM EDT Zacks Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
03/13/2025 12:15 PM EDT Zacks Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
03/12/2025 08:30 PM EDT Zacks Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
03/12/2025 08:00 PM EDT SeekingAlpha Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript
03/12/2025 07:00 PM EDT Zacks Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
03/12/2025 05:20 PM EDT Zacks Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
03/12/2025 04:18 PM EDT SeekingAlpha Nektar Therapeutics Non-GAAP EPS of $0.15 beats by $0.35, revenue of $29.17M misses by $7.49M
03/12/2025 10:00 AM EDT SeekingAlpha Here are the major earnings after the close today
03/11/2025 05:35 PM EDT SeekingAlpha Nektar Therapeutics Q4 2024 Earnings Preview
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.